Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Radiation Oncology
•
CNS Disease
What activity restrictions do you counsel patients on after radiosurgery for arteriovenous malformations, given the continued risk of hemorrhage until nidus obliteration?
Related Questions
How would you treat a painful peripancreatic schwannoma in the setting of prior SBRT course?
Would you consider delaying tarlatamab initiation in a patient with ES SCLC who recently completed RT for CNS disease, given the concern for immune effector cell-associated neurotoxicity syndrome (ICANS)?
How will you select patients with brain metastases for TTFields?
Would you prefer SBRT or fractionated radiation for a sacral peripheral nerve sheath tumor?
Would you offer re-irradiation for a prostate local recurrence after I-125 seed implant >10 years ago in a healthy young patient with life expectancy >15 years?
In light of Aizer et al. data presented at ASCO 2025, what is your threshold for offering SRS/SRT in patients with multiple brain metastases?
What target expansions do you use when treating with 60 Gy in 15 fractions for the lung?
How long would you stop standard GBM radiotherapy if the patient had a fall with minor head trauma?
Do you see MR Linac having a role in the treatment of CNS disease?
When treating an inoperable urothelial cancer of the renal pelvis, what are your considerations when determining candidacy for SBRT?
